{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:42:36Z","timestamp":1793353356653,"version":"4.5.0"},"reference-count":279,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clindermatol.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:06:18Z","timestamp":1593176778000},"page":"712-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Adverse cutaneous reactions to chemotherapeutic drugs"],"prefix":"10.1016","volume":"38","author":[{"given":"Dylan","family":"Haynes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.06.007_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1590\/S0365-05962010000500002","article-title":"Adverse mucocutaneous reactions related to chemotherapeutic agents: part II","volume":"85","author":"Criado","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1590\/S0365-05962010000400003","article-title":"Adverse mucocutaneous reactions to chemotherapeutic agents: part I","volume":"85","author":"Sanches Junior","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0025","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s12094-018-1891-7","article-title":"Cutaneous toxicities of new treatments for melanoma","volume":"20","author":"Boada","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0030","doi-asserted-by":"crossref","first-page":"5376476","DOI":"10.1155\/2018\/5376476","article-title":"Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies","volume":"2018","author":"Ng","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0035","doi-asserted-by":"crossref","unstructured":"Dai J, Belum VR, Wu S, et al. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77:902-910.e902.","DOI":"10.1016\/j.jaad.2017.06.044"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/DAD.0000000000000504","article-title":"Cutaneous reactions to targeted therapy","volume":"39","author":"Lee","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0060","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/archdermatol.2011.719","article-title":"Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents","volume":"147","author":"Borovicka","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/030089161209800402","article-title":"The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience","volume":"98","author":"Giuliani","year":"2012","journal-title":"Tumori"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0070","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0075","series-title":"Clinical Aspects of Immunology","author":"Gell","year":"1968"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0080","doi-asserted-by":"crossref","DOI":"10.4081\/pr.2012.e28","article-title":"Extravasation of antineoplastic agents: prevention and treatments","volume":"4","author":"Boschi","year":"2012","journal-title":"Pediatr Rep"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0085","doi-asserted-by":"crossref","first-page":"856541","DOI":"10.1155\/2013\/856541","article-title":"Extravasation injuries in adults","volume":"2013","author":"Al-Benna","year":"2013","journal-title":"ISRN Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5306\/wjco.v7.i1.87","article-title":"Overview, prevention and management of chemotherapy extravasation","volume":"7","author":"Kreidieh","year":"2016","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0095","first-page":"173","article-title":"Persistence of anthracycline levels following dermal and subcutaneous Adriamycin extravasation","volume":"22","author":"Garnick","year":"1981","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-0560.1989.tb00032.x","article-title":"Histologic changes induced in skin by extravasation of doxorubicin (adriamycin)","volume":"16","author":"Bhawan","year":"1989","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminoncol.2005.11.007","article-title":"Extravasation of chemotherapeutic agents: prevention and treatment","volume":"33","author":"Goolsby","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(80)80023-5","article-title":"Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs","volume":"7","author":"Ignoffo","year":"1980","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/1097-0142(197609)38:3<1087::AID-CNCR2820380308>3.0.CO;2-X","article-title":"Skin ulcers due to adriamycin","volume":"38","author":"Rudolph","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/1097-0142(1971)28:4<837::AID-CNCR2820280406>3.0.CO;2-4","article-title":"Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease","volume":"28","author":"Wang","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0125","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2003.99.095","article-title":"Extravasations of oxaliplatin","volume":"21","author":"Kretzschmar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0130","first-page":"468","article-title":"Extravasation of oxaliplatin (Eloxatin\u00ae) \u2013 clinical course","volume":"23","author":"Baur","year":"2000","journal-title":"Onkologie"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdg252","article-title":"A case report of oxaliplatin extravasation","volume":"14","author":"Foo","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0140","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1188\/06\/ONF.1143-1150","article-title":"Vesicant extravasation part II: evidence-based management and continuing controversies","volume":"33","author":"Wickham","year":"2006","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00002018-199512040-00004","article-title":"Prevention and management of extravasation of cytotoxic drugs","volume":"12","author":"Bertelli","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0150","doi-asserted-by":"crossref","unstructured":"Perez Fidalgo JA, Garcia Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2012;23(suppl 7):vii167-173.","DOI":"10.1093\/annonc\/mds294"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0155","first-page":"347","article-title":"Systemic therapy emergencies","volume":"27","author":"Albanell","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/BF00686305","article-title":"Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach","volume":"30","author":"Tsavaris","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0165","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/1097-0142(19800415)45:8<2225::AID-CNCR2820450836>3.0.CO;2-8","article-title":"Accidental intramuscular injection of mechlorethamine","volume":"45","author":"Owen","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.soncn.2010.11.010","article-title":"Extravasation management: clinical update","volume":"27","author":"Schulmeister","year":"2011","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0175","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/annonc\/mdt024","article-title":"Reply to \u2018comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines\u2019","volume":"24","author":"Perez-Fidalgo","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1188\/09.CJON.395-398","article-title":"Vesicant chemotherapy extravasation antidotes and treatments","volume":"13","author":"Schulmeister","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF01191807","article-title":"Hyaluronidase as an antidote to extravasation ofVinca alkaloids: clinical results","volume":"120","author":"Bertelli","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/annonc\/mdl413","article-title":"Successful treatment of anthracycline extravasation with savene (dexrazoxane) \u2013 results from two prospective clinical multicenter studies","volume":"18","author":"Mouridsen","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0195","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1634\/theoncologist.2007-0247","article-title":"Dexrazoxane (Totect\u2122): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy","volume":"13","author":"Kane","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0200","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0205","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-015-2546-1","article-title":"Hand-foot syndrome following decitabine","volume":"95","author":"Ali","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0210","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/archdermatol.2011.320","article-title":"Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature","volume":"147","author":"Hoesly","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","article-title":"Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin","volume":"26","author":"Yokomichi","year":"2013","journal-title":"Hum Cell"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0220","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia","volume":"29","author":"Martschick","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0225","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy \u2013 classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"JDDG"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0230","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","article-title":"Chemotherapy-induced acral erythema","volume":"24","author":"Baack","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0235","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0240","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.cnd.0000211401.19995.a2","article-title":"Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report","volume":"7","author":"Stubblefield","year":"2006","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0245","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome: incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0250","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archderm.1997.03890430089012","article-title":"Chemotherapy-induced eccrine squamous syringometaplasia: a distinctive eruption in patients receiving hematopoietic progenitor cells","volume":"133","author":"Valks","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0255","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/archderm.1986.01660210073021","article-title":"Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation","volume":"122","author":"Crider","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0260","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Farr","year":"2011","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0265","unstructured":"Titgan M. Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone. Proc Am Soc Clin Oncol. 1997;16:82a."},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0270","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0190-9622(08)80126-0","article-title":"Treatment of cytarabine acral erythema with corticosteroids","volume":"24","author":"Brown","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0275","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1002\/cncr.25262","article-title":"A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients","volume":"116","author":"von Gruenigen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0280","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.2012.318","article-title":"A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications","volume":"107","author":"Corrie","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0290","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00685939","article-title":"Etoposide-related acral erythema","volume":"34","author":"Portal","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0300","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ced.12538","article-title":"Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis","volume":"40","author":"Jo","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0305","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","article-title":"Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial","volume":"23","author":"Zhang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0310","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0315","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-4632.2006.02606.x","article-title":"Neutrophilic eccrine hidradenitis in non-small cell lung cancer","volume":"46","author":"Lee","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0320","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1191\/0961203303lu420cr","article-title":"Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide","volume":"12","author":"Lienesch","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0378-6323.30662","article-title":"Urticarial papules and plaques on the trunk","volume":"73","author":"Narang","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0330","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0190-9622(84)70210-6","article-title":"Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia","volume":"11","author":"Flynn","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0335","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/j.leukres.2009.11.026","article-title":"Neutrophilic eccrine hidradenitis associated with decitabine","volume":"34","author":"Ng","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0340","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/1097-0142(19881215)62:12<2532::AID-CNCR2820621214>3.0.CO;2-D","article-title":"Neutrophilic eccrine hidradenitis. Evidence implicating bleomycin as a causative agent","volume":"62","author":"Scallan","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0345","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17843286.1993.11718336","article-title":"Neutrophilic eccrine hidradenitis. A case report","volume":"48","author":"Nikkels","year":"1993","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0350","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/15569527.2011.627077","article-title":"Neutrophilic eccrine hidradenitis induced by cetuximab","volume":"31","author":"Turan","year":"2012","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0355","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/bjd.15259","article-title":"Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event","volume":"176","author":"Herms","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0360","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.leukres.2004.05.015","article-title":"Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy","volume":"29","author":"Dib","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0365","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/09546630252775234","article-title":"Neutrophilic eccrine hidradenitis secondary to topotecan","volume":"13","author":"Marini","year":"2002","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0370","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jaad.2017.11.064","article-title":"Neutrophilic dermatoses: pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behcet disease","volume":"79","author":"Nelson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archderm.1982.01650160053024","article-title":"Neutrophilic eccrine hidradenitis: a distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy","volume":"118","author":"Harrist","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0380","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0190-9622(94)70215-2","article-title":"Sweet\u2019s syndrome (acute febrile neutrophilic dermatosis)","volume":"31","author":"von den Driesch","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0385","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0738-081X(99)00123-6","article-title":"Neutrophilic eccrine hidradenitis","volume":"18","author":"Bachmeyer","year":"2000","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0390","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.ad.2013.04.016","article-title":"Infectious eccrine hidradenitis: a report of 3 cases and a review of the literature","volume":"105","author":"Bassas-Vila","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0395","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0190-9622(96)90092-4","article-title":"Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis","volume":"35","author":"Shear","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0400","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ijd.13040","article-title":"Syringometaplasia: variants and underlying mechanisms","volume":"55","author":"Abbas","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0405","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jdcr.2016.11.001","article-title":"Pemetrexed-induced eccrine squamous syringometaplasia manifesting as pseudocellulitis (in a patient with non-small cell lung cancer)","volume":"3","author":"Santosa","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0410","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1346-8138.2005.tb00873.x","article-title":"A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature","volume":"32","author":"Tsuboi","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0415","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.jaad.2013.06.049","article-title":"Eccrine squamous syringometaplasia associated with dabrafenib therapy","volume":"69","author":"Liuti","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0420","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/1346-8138.13076","article-title":"Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin-bound paclitaxel","volume":"42","author":"Fujii","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0425","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1525-1470.2008.00809.x","article-title":"Vincristine-induced eccrine squamous syringometaplasia","volume":"25","author":"Thomas","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/archderm.1990.01670250079013","article-title":"Eccrine squamous syringometaplasia. A cutaneous sweat gland reaction in the histologic spectrum of \u2018chemotherapy-associated eccrine hidradenitis\u2019 and \u2018neutrophilic eccrine hidradenitis\u2019","volume":"126","author":"Hurt","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0435","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","article-title":"Mucocutaneous reactions to chemotherapy","volume":"40","author":"Susser","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0440","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-0560.1979.tb01136.x","article-title":"Syringometaplasia: mucinous and squamous variants","volume":"6","author":"King","year":"1979","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0445","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1578::AID-CNCR23>3.0.CO;2-W","article-title":"Localized cisplatin hyperpigmentation induced by pressure. A case report","volume":"77","author":"Al-Lamki","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0450","doi-asserted-by":"crossref","unstructured":"Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71:203.e201-203.e212; quiz 215-206.","DOI":"10.1016\/j.jaad.2014.04.014"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0455","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11096-013-9756-1","article-title":"Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation","volume":"35","author":"Youssef","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0460","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-4362.1995.tb01579.x","article-title":"Reticulate pigmentation due to 5-fluorouracil","volume":"34","author":"Allen","year":"1995","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0465","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0470","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(01)06650-8","article-title":"Clinical picture: leopard-like vitiligo with capecitabine","volume":"358","author":"Schmid-Wendtner","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0475","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.lungcan.2013.02.019","article-title":"Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma","volume":"80","author":"Buchinger","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0480","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1067\/mjd.2000.106239","article-title":"Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine","volume":"43","author":"Marcoux","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0485","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mjd.2002.104509","article-title":"Generalized hyperpigmentation with daunorubicin chemotherapy","volume":"46","author":"Kroumpouzos","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0490","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1468-3083.2005.01088.x","article-title":"Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel","volume":"19","author":"Aydogan","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00128071-200102040-00006","article-title":"Drug-induced skin pigmentation","volume":"2","author":"Dereure","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0500","doi-asserted-by":"crossref","unstructured":"Grynszpan R, Niemeyer-Corbellini JP, Lopes MS, et al. Bleomycin-induced flagellate dermatitis. BMJ Case Rep. 2013;2013:bcr2013009764.","DOI":"10.1136\/bcr-2013-009764"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0505","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00128071-200607010-00005","article-title":"Cutaneous reactions to chemotherapy and their management","volume":"7","author":"Wyatt","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0510","series-title":"Dermatologic Principles and Practice in Oncology Conditions of the Skin, Hair, and Nails in Cancer Patients","author":"Lacouture","year":"2013"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0515","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1634\/theoncologist.2017-0263","article-title":"A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention","volume":"23","author":"Dunnill","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0520","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2011.02.026","article-title":"Chemotherapy-induced alopecia","volume":"67","author":"Chon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0525","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair disorders in patients with cancer","volume":"80","author":"Freites-Martinez","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0530","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.5021\/ad.2011.23.S3.S350","article-title":"A case of cicatricial alopecia associated with erlotinib","volume":"23","author":"Yang","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0535","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archderm.144.11.1524","article-title":"Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib","volume":"144","author":"Donovan","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0540","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","article-title":"Permanent chemotherapy-induced alopecia: case report and review of the literature","volume":"63","author":"Tallon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0545","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jaad.2018.03.056","article-title":"Hair disorders in cancer survivors","volume":"80","author":"Freites-Martinez","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0550","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","article-title":"Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0555","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1590\/abd1806-4841.20154013","article-title":"Clinical and histological study of permanent alopecia after bone marrow transplantation","volume":"90","author":"Basilio","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0560","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10549-009-0342-0","article-title":"Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling","volume":"118","author":"Lemieux","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0565","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1529-8019.2011.01430.x","article-title":"Treatment of chemotherapy-induced alopecia","volume":"24","author":"Yeager","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0570","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0575","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clbc.2015.01.003","article-title":"Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients receiving adjuvant docetaxel and cyclophosphamide chemotherapy","volume":"15","author":"Cigler","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0580","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0959-8049(00)00012-5","article-title":"Prevention of chemotherapy-induced alopecia using an effective scalp cooling system","volume":"36","author":"Katsimbri","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.04.012","article-title":"Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline\/taxane-based chemotherapy","volume":"40","author":"Vasconcelos","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0590","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/oxfordjournals.annonc.a058986","article-title":"Minoxidil (Mx) as a prophylaxis of doxorubicin\u2014induced alopecia","volume":"5","author":"Rodriguez","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0595","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"A randomized trial of minoxidil in chemotherapy-induced alopecia","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0600","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/annonc\/mds095","article-title":"Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients","volume":"23","author":"Kluger","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0605","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jaad.2016.12.027","article-title":"Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: clinicopathologic findings in a cohort of 10 patients","volume":"76","author":"Fonia","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0610","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archdermatol.2010.258","article-title":"Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy","volume":"146","author":"Funke","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0615","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1200\/JCO.2011.35.0686","article-title":"Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil","volume":"29","author":"Almagro","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0620","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2007.06.040","article-title":"Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine","volume":"59","author":"Weger","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0625","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamadermatol.2013.4957","article-title":"Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent","volume":"149","author":"Wiznia","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0630","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/j.1365-2230.2009.03280.x","article-title":"Subacute cutaneous lupus erythematosus induced by capecitabine","volume":"34","author":"Floristan","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0635","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.jaad.2012.05.021","article-title":"Drug-induced subacute cutaneous lupus erythematosus associated with doxorubicin","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0640","first-page":"818","article-title":"Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0645","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1346-8138.2007.00313.x","article-title":"Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA\/Ro antibody","volume":"34","author":"Adachi","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0650","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00403-008-0890-x","article-title":"Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation","volume":"301","author":"Sontheimer","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0655","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0961203309103050","article-title":"Chemotherapy-induced subacute lupus erythematosus","volume":"18","author":"Guhl","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0660","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1684\/ejd.2016.2912","article-title":"Drug-induced cutaneous lupus erythematosus: 88 new cases","volume":"27","author":"Laurinaviciene","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0665","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0670","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.iac.2015.01.011","article-title":"Anaphylaxis to chemotherapy and monoclonal antibodies","volume":"35","author":"Castells","year":"2015","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0675","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1001\/archinte.1978.03630360097038","article-title":"Cyclophosphamide-induced urticaria. Occurrence in a patient with no cross-sensitivity to chlorambucil","volume":"138","author":"Krutchik","year":"1978","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0680","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0091-6749(76)90151-2","article-title":"Generalized urticaria to cyclophosphamide: type I hypersensitivity to an immunosuppressive agent","volume":"58","author":"Lakin","year":"1976","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0685","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archderm.1977.01640090146037","article-title":"Cutaneous reaction to chlorambucil","volume":"113","author":"Millard","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0690","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2133.1976.tb04350.x","article-title":"Contact urticaria and anaphylactoid reaction induced by topical application of nitrogen mustard","volume":"94","author":"Grunnet","year":"1976","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0695","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0091-6749(76)90032-4","article-title":"Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity","volume":"57","author":"Glovsky","year":"1976","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0700","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-911X(199910)33:4<420::AID-MPO19>3.0.CO;2-B","article-title":"Skin toxicity after administration of low-dose cytarabine","volume":"33","author":"Kantar","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0705","first-page":"226","article-title":"Serious allergic reaction to administration of epirubicin","volume":"61","author":"Oltmans","year":"2003","journal-title":"Neth J Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0710","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02985165","article-title":"Hypersensitivity reaction to epirubicin","volume":"6","author":"Cassidy","year":"1989","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0715","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fimmu.2017.01472","article-title":"Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations","volume":"8","author":"Castells","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0720","first-page":"307","article-title":"Successful oral desensitization in a patient with hypersensitivity reaction to crizotinib","volume":"25","author":"Sanchez-Lopez","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0725","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0730","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0735","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/1078155214565126","article-title":"Sorafenib-induced severe urticaria in a patient with hepatocellular cancer","volume":"22","author":"Musri","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0740","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0745","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","article-title":"Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization","volume":"2","author":"Wong","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0750","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3349\/ymj.2019.60.2.119","article-title":"Desensitization for allergic reactions to chemotherapy","volume":"60","author":"Hong","year":"2019","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0755","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000339690","article-title":"Nonallergic drug hypersensitivity reactions","volume":"159","author":"Farnam","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0760","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","article-title":"Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments","volume":"96","author":"Feldweg","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0765","unstructured":"McEvoy GK, American Society of Health-System Pharmacists. AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2008."},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0770","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/s12885-017-3848-6","article-title":"Leukocytoclastic vasculitis complicating cisplatin + radiation treatment for laryngeal cancer: a case report","volume":"17","author":"Quintanilha","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0775","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000357166","article-title":"Oxaliplatin-induced leukocytoclastic vasculitis under adjuvant chemotherapy for colorectal cancer: two cases of a rare adverse event","volume":"6","author":"Quack","year":"2013","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0780","first-page":"862","article-title":"Small vessel vasculitis related to 5-fluorouracil and folinic acid","volume":"20","author":"Pellegrini","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0785","first-page":"E40","article-title":"Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer","volume":"6","author":"Al-Shamsi","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0790","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1034\/j.1600-0536.2000.042002074.x","article-title":"Type III and type IV hypersensitivity reactions due to mitomycin C","volume":"42","author":"Kunkeler","year":"2000","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0795","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/annonc\/mdm420","article-title":"Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib","volume":"18","author":"Boeck","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0800","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13256-018-1877-7","article-title":"Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report","volume":"13","author":"Kamo","year":"2019","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0805","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jamadermatol.2017.5733","article-title":"Erythema nodosum-like eruption in the setting of sorafenib therapy","volume":"154","author":"Coleman","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0810","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1684\/ejd.2012.1915","article-title":"Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma","volume":"23","author":"Degen","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0815","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-015-0545-9","article-title":"Drug-induced vasculitis: new insights and a changing lineup of suspects","volume":"17","author":"Grau","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0820","series-title":"StatPearls [Internet]","article-title":"Leukocytoclastic Vasculitis (Hypersensitivity Vasculitis) [Updated 2020 Jul 4]","author":"Baigrie","year":"2020"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0825","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archderm.1990.01670250075012","article-title":"Cutaneous leukocytoclastic vasculitis. Serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate","volume":"126","author":"Zax","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0830","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/archderm.135.11.1349","article-title":"A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas","volume":"135","author":"Esteve","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0835","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1365-2133.2002.04802.x","article-title":"Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment","volume":"147","author":"Foulc","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0840","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1523-1747.ep12345517","article-title":"Detection of low-level tumor cells in allergic contact dermatitis induced by mechlorethamine in patients with mycosis fungoides","volume":"106","author":"Veelken","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0845","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40521-015-0064-y","article-title":"Another great imitator: allergic contact dermatitis differential diagnosis, clues to diagnosis, histopathology, and treatment","volume":"2","author":"So","year":"2015","journal-title":"Curr Treat Options Allergy"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0850","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000187429","article-title":"Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia","volume":"83","author":"Vaida","year":"2009","journal-title":"Pharmacology"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0855","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0865","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.leukres.2008.08.023","article-title":"Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma","volume":"33","author":"Hattori","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0870","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0378-6323.198452","article-title":"A new case of imatinib-induced drug reaction with eosinophilia and systemic symptoms","volume":"83","author":"Saidi","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0875","doi-asserted-by":"crossref","unstructured":"Goldman J, Duval-Modeste AB, Lambert A, et al. [Imatinib-induced DRESS]. Ann Dermatol Venereol. 2008;135:393-396.","DOI":"10.1016\/j.annder.2007.10.007"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0880","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0151-9638(06)70992-9","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy","volume":"133","author":"Le Nouail","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0885","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000439272","article-title":"Early-onset vemurafenib-induced DRESS syndrome","volume":"232","author":"Munch","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0890","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamadermatol.2013.5278","article-title":"Vemurafenib-induced DRESS","volume":"149","author":"Wenk","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0895","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaad.2018.07.029","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: a series of 11 cases","volume":"80","author":"Bregeon","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0900","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jaad.2013.11.018","article-title":"Drug hypersensitivity syndrome in a patient receiving vismodegib","volume":"70","author":"Lam","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0905","first-page":"15","article-title":"Testing for drug hypersensitivity syndromes","volume":"34","author":"Rive","year":"2013","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0910","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaip.2016.10.009","article-title":"Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: an immunohistochemical study","volume":"5","author":"Hansel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0915","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0920","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0925","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0930","doi-asserted-by":"crossref","unstructured":"Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1-14; quiz 706-708.","DOI":"10.1016\/j.jaad.2013.01.033"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0935","doi-asserted-by":"crossref","unstructured":"Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.e701-709; quiz 718-720.","DOI":"10.1016\/j.jaad.2013.01.032"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0940","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.leukres.2012.03.006","article-title":"Stevens-Johnson syndrome after treatment with bendamustine","volume":"36","author":"Lambertini","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0945","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-2133.1996.tb03915.x","article-title":"Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases","volume":"135","author":"Assier-Bonnet","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0950","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0190-9622(97)70341-4","article-title":"Stevens-Johnson syndrome associated with topical nitrogen mustard therapy","volume":"36","author":"Newman","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0955","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1631\/jzus.B1700065","article-title":"Toxic epidermal necrolysis after dactinomycin and vincristine combination chemotherapy for nephroblastoma","volume":"18","author":"Liang","year":"2017","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0960","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2340\/00015555-2027","article-title":"Stevens-Johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient","volume":"95","author":"Honda","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0965","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0970","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000102604","article-title":"Severe epidermal necrolysis after bortezomib treatment for multiple myeloma","volume":"118","author":"Fang","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0975","first-page":"233","article-title":"et al","volume":"42","author":"Mihara","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0980","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/1346-8138.12219","article-title":"Case of sunitinib-induced Stevens-Johnson syndrome","volume":"40","author":"Lee","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0985","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0990","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.14052","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies","volume":"173","author":"Wu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb0995","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1000","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CCM.0b013e31829eb94f","article-title":"Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation","volume":"42","author":"de Prost","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000195632","article-title":"Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"29","author":"Hung","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archderm.141.6.683","article-title":"Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis","volume":"141","author":"Quinn","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1020","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1025","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jaad.2010.06.032","article-title":"Azacitidine: a new medication associated with Sweet syndrome","volume":"64","author":"Tintle","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1030","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2146\/ajhp110523","article-title":"Azacitidine-associated Sweet\u2019s syndrome","volume":"69","author":"Trickett","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1035","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1684\/ejd.2012.1861","article-title":"Histiocytoid Sweet\u2019s syndrome potentially related to decitabine in a patient with myelodysplastic syndrome","volume":"22","author":"Park","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/1352458510390069","article-title":"Drug-induced Sweet\u2019s syndrome after mitoxantrone therapy in a patient with multiple sclerosis","volume":"17","author":"K\u00fcmpfel","year":"2011","journal-title":"Mult Scler J"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1045","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jaad.2013.11.022","article-title":"Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma","volume":"70","author":"Kyllo","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1050","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2014.06.042","article-title":"Ipilimumab-associated Sweet syndrome in a melanoma patient","volume":"71","author":"Gormley","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet\u2019s syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1060","unstructured":"Van Regenmortel N, Van de Voorde K, De Raeve H, et al. Bortezomib-induced Sweet\u2019s syndrome. Haematologica. 2005;90:Ecr43."},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.annder.2008.10.039","article-title":"Bortezomib-induced eruption: Sweet syndrome? Two case reports","volume":"136","author":"Thuillier","year":"2009","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1070","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2008.09.007","article-title":"Bortezomib-induced histiocytoid Sweet syndrome","volume":"60","author":"Murase","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1075","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CMR.0000000000000438","article-title":"Histiocytoid Sweet\u2019s syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma","volume":"28","author":"Morgado-Carrasco","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1080","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archderm.144.3.361","article-title":"Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells","volume":"144","author":"Kaune","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bjh.13334","article-title":"Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis","volume":"169","author":"Chatterjee","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1095","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/1346-8138.12430","article-title":"Case of vemurafenib-induced Sweet\u2019s syndrome","volume":"41","author":"Yorio","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cup.12273","article-title":"Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma","volume":"41","author":"Pattanaprichakul","year":"2014","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gynor.2013.01.002","article-title":"Topotecan-induced Sweet\u2019s syndrome: a case report","volume":"4","author":"Dickson","year":"2013","journal-title":"Gynecol Oncol Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2019.00414","article-title":"Insights into the pathogenesis of Sweet\u2019s syndrome","volume":"10","author":"Heath","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1115","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0190-9622(96)90080-8","article-title":"Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet\u2019s syndrome","volume":"34","author":"Walker","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1120","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archderm.141.7.834","article-title":"Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes","volume":"141","author":"Requena","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1125","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/archderm.142.9.1170","article-title":"Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases","volume":"142","author":"Vignon-Pennamen","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaad.2012.12.954","article-title":"Subcutaneous Sweet syndrome in the setting of myeloid disorders: a case series and review of the literature","volume":"68","author":"Chan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cup.12921","article-title":"Cryptococcoid Sweet\u2019s syndrome: two reports of Sweet\u2019s syndrome mimicking cutaneous cryptococcosis","volume":"44","author":"Wilson","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2014.01.874","article-title":"Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization","volume":"70","author":"Chavan","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2017.09.016","article-title":"Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis","volume":"119","author":"Li","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00277-015-2538-1","article-title":"Brentuximab-induced hand-foot syndrome in a Hodgkin lymphoma patient","volume":"95","author":"Rehman","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ced.12694","article-title":"Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis","volume":"41","author":"Belum","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1160","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1111\/j.1365-4632.2012.05780.x","article-title":"Hand-foot syndrome induced by erlotinib (Tarceva\u00ae)","volume":"53","author":"Cho","year":"2014","journal-title":"Int J Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2020.06.007_bb1165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0959-8049(09)70044-9","article-title":"Skin toxicities of targeted therapies","volume":"45","author":"Segaert","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1170","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474124.2017.1373018","article-title":"Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis","volume":"12","author":"Wang","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1185","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1634\/theoncologist.12-10-1178","article-title":"Localized palmar\u2013plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib","volume":"12","author":"Beldner","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1190","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5114\/ada.2017.71106","article-title":"The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors","volume":"34","author":"Owczarek","year":"2017","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1200","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1205","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/pbc.25429","article-title":"Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis","volume":"62","author":"Belum","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1210","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1200\/JCO.2010.32.9458","article-title":"Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma","volume":"29","author":"Hsiao","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/02841860903104152","article-title":"Case studies showing clinical signs and management of cutaneous toxicity of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours","volume":"49","author":"Desar","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D34RG64357","article-title":"Facial acneiform rash associated with sorafenib","volume":"15","author":"Fleta-Asin","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1225","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1230","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1235","first-page":"351210","article-title":"Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management","volume":"2012","author":"Abdullah","year":"2012","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform rash induced by EGFR inhibitors: review of the literature and new insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1245","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cup.12202","article-title":"Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors","volume":"40","author":"Brodell","year":"2013","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1255","doi-asserted-by":"crossref","unstructured":"Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol. 2014;71:217.e211; quiz 227-218.","DOI":"10.1016\/j.jaad.2014.04.013"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1260","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1265","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/JTO.0b013e3181ec1729","article-title":"Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer","volume":"5","author":"Bidoli","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1270","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1275","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1285","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1290","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1295","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2014small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1305","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fonc.2018.00616","article-title":"Predictive value of cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"8","author":"Uozumi","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1310","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1315","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12253-017-0238-y","article-title":"Predictive value of early skin rash in cetuximab-based therapy of advanced biliary tract cancer","volume":"24","author":"Rubovszky","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1320","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","article-title":"The SCF\/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis","volume":"111","author":"Grichnik","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1325","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/mjd.2001.112221","article-title":"A novel KIT mutation results in piebaldism with progressive depigmentation","volume":"44","author":"Richards","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1330","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jama.293.6.730","article-title":"New insights and new therapies in vitiligo","volume":"293","author":"Grimes","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1335","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3472203P2","article-title":"Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST","volume":"14","author":"Alexandrescu","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1340","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/DAD.0b013e3181a23f3b","article-title":"Melanoma hyperpigmentation is strongly associated with KIT alterations","volume":"31","author":"Wu","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1345","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/ijd.13931","article-title":"Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature","volume":"57","author":"Di Tullio","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1355","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1360","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1365","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1370","doi-asserted-by":"crossref","unstructured":"Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519.","DOI":"10.1155\/2013\/857519"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1375","first-page":"4062431","article-title":"Dasatinib-induced hypopigmentation in pediatric patient with chronic myeloid leukemia: a case report and review of the literature","volume":"2018","author":"Alharbi","year":"2018","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1380","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1385","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1390","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.5301\/tj.5000253","article-title":"Association of vitiligo and response in patients with metastatic malignant melanoma on temozolomide","volume":"101","author":"Tatli","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.clindermatol.2020.06.007_bb1395","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Nov 27, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf (accesed: Mar 1, 2018)."}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20301401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20301401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:18:35Z","timestamp":1760033915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20301401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":279,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0738081X20301401"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.007","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse cutaneous reactions to chemotherapeutic drugs","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}